This is supported by the results of a study of 119 patients with malignant gliomas that compared neurocognitive performance according to IDH1 mutation status (7); IDH1 wild type tumors, which generally more aggressive and grow faster, are associated with reduced neurocognitive function compared to those with IDH1 mutant tumors. This evidence concerns the gene IDH1 and malignant glioma.